QUIBIM S.L. was created in late 2012 as an initiative from a group of doctors in biomedical engineering and a Key Opinion Leader in radiology with a recognized international scientific career.

We are a reference core lab in imaging biomarkers extraction and analysis, born as a spin-off of La Fe Health Research Institute in Valencia (Spain), the renowned research institute of La Fe Polytechnics and University Hospital.

QUIBIM applies advanced computational models to radiological images to objectively measure changes produced by a lesion or by a pharmacological treatment, offering additional quantitative information to the qualitative approach of radiology.

Our company provides state of the art solutions for early diagnosis, lesion grading-phenotyping-staging, treatment selection/follow-up, in addition to the validation against clinical endpoints.

First national customers and Application for FP7 consortiums.

First international customer (US)
Development of new algorithms
Patent application (lung emphysema)
Development of the business model
Spin-off company of IIS La Fe

LANZADERA business acceleration program
Development of QUIBIM Precision (Cloud & Local solutions)
Ongoing customers
Definition of marketing & sales strategy
Joint Venture with FEEDBACK to develop Prostate Checker
TexRAD application.

Scaling and growth phase
Booth at the European Congress of Radiology (ECR 2016)
New customers
Investment round



Ángel Alberich-Bayarri  
Founder and CEO
Katherine Wilisch
Coordinator and CEO Support
Encarna Sánchez
Business Development Manager
Rafael Hernández
Chief Technology Officer
Alejandro Mañas
Full Stack Senior Developer
Fabio García
R&D Responsible
Irene Mayorga Ruiz
Image Analysis Scientist



Adaptive lung segmentation

LUNG EMPHYSEMA Patent application; 201.331.295. Segmentation method by adaptative thresholding for the obtention of air reference values slice-by-slice in CT imaging studies.



Forner Giner J, Sanz-Requena R, Flórez N, Alberich-Bayarri A,García-Martí G, Ponz A, Martí-Bonmatí L. Quantitative phase-contrast MRI study of cerebrospinal fluid flow: a method for identifying patients with normal-pressure hydrocephalus. Neurologia. 2014 Mar;29(2):68-75. doi: 10.1016/j.nrl.2013.02.016. Epub 2013 May 3 English, Spanish. PubMed PMID: 23643684

Arana E, Martínez-Granados B, Marti-Bonmati L, Martínez-Bisbal MC, Gil A, Blasco C, Celda B. [Dementias: diagnostic contribution of imaging and proton magnetic resonance spectroscopy]. Neurologia. 2007 Jun; 22(5):267-74. Spanish. PubMed PMID: 17508300

Magraner MJ, Bosca I, Simó-Castelló M, García-Martí G, Alberich-Bayarri A, Coret F, Alvarez-Cermeño JC, Martí-Bonmatí L, Villar LM, Casanova B. Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology. 2012 Jan;54(1):5-12. doi: 10.1007/s00234-011-0841-7. Epub 2011 Feb 16. PubMed PMID: 21327771

Martínez-Bisbal MC, Arana E, Martí-Bonmatí L, Martínez-Granados B, Celda B. [Cognitive impairment: classification by proton magnetic resonance spectroscopy and the contributions of conventional magnetic resonance imaging]. Radiologia. 2006 Sep-Oct; 48(5):301-7. Spanish. PubMed PMID: 17168239

Proal E, Alvarez-Segura M, de la Iglesia-Vayá M, Martí-Bonmatí L, Castellanos FX; Spanish Resting State Network. [Functional cerebral activity in a state of rest: connectivity networks]. Rev Neurol. 2011 Mar 1; 52 Suppl 1:S3-10. Spanish. PubMed PMID: 21365601; PubMed Central PMCID: PMC4418791.

Martínez-Bisbal MC, Arana E, Martí-Bonmatí L, Mollá E, Celda B. Cognitive impairment: classification by 1H magnetic resonance spectroscopy. Eur J Neurol. 2004 Mar; 11(3):187-93. PubMed PMID: 15009164